Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial

Blood

Volumn 112, Issue 8, 2008, Pages 3107-3114

  Palumbo, Antonio ^a   Bringhen, Sara ^a   Liberati, Anna M ^b   Caravita, Tommaso ^c   Falcone, Antonietta ^d   Callea, Vincenzo ^e   Montanaro, Marco ^f   Ria, Roberto ^g   Capaldi, Antonio ^h   Zambello, Renato ⁱ   Benevolo, Giulia ^j   Derudas, Daniele ^k   Dore, Fausto ^l   Cavallo, Federica ^a   Gay, Francesca ^a   Falco, Patrizia ^a   Ciccone, Giovannino ^a   Musto, Pellegrino ^m   Cavo, Michele ⁿ   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b POLICLINICO MONTELUCE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^f Unità Operativa Complessa di Ematologia   (United States)

^g POLICLINICO   (Italy)

^h CANDIOLO CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^j MOLINETTE HOSPITAL   (Italy)

^k Ospedale Oncologico A Businco   (Italy)

^l UNIVERSITY OF SASSARI   (Italy)

^m REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; DELTACORTENE F; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; MELPHALAN; PHARMION; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CISPLATIN; METHOTREXATE; MP REGIMEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SKIN DISEASE; THROMBOEMBOLISM; AGE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MELPHALAN; METHOTREXATE; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 54049135250     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-149427     Document Type: Article

References (22)

1. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165-2172.
2. San Miguel JF, Schlag R, Khuageva N, et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma [Abstract]. Blood. 2007;110: 76.
3. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465.
4. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005: 104:1428-1433.
5. Dimopoulos MA, Anagnostopoulos A, Terpos E, et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica. 2006;91:252-254.
6. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367:825-831.
7. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-1218.
8. Hulin C, Facon T, Rodon P, et al. Melphalanprednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood. 2007;110:75.
9. Waage A, Gimsing P, Juliusson G, et al. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomized phase 3 trial [abstract]. Blood. 2007:110:78.
10. Durie BG, Salmon SE. Aclinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975:36:842-854.
11. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group: international uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
13. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, version 2.0, DCTD, NCI, NIH, DHHSApril 30, 1999. http://ctep.cancer.gov.
14. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958:53:457-478.
15. Cox DR. Regression model and life-tables (with discussion). J R Stat Soc B. 1972;34:187-220.
16. Greipp PR, San Miguel J, Durie BG, etal. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
17. Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007;2007:317-323.
18. Shigal S, Metha J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
19. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968-3977.
20. Richardson PG, Barlogie B, Berenson J, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
21. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexametasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487-2498.
22. Falco P, Bringhen S, Avonto I, et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2007;7:945-957.